lbl-033
mAbexperimentalBi-specific
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 14, 2023 (NCT05779163)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
CD3E activator
- Mucin-16Immunity, active
MUC16 immunity, active
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05779163 | Phase 1/Phase 2 (Phase 2) | Apr 14, 2023 | Nanjing Leads Biolabs Co.,Ltd, Sun Yat-Sen University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nanjing Leads Biolabs Co.,Ltd | For profit | 1 | 1 | 1 | 2023 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1